Table 3.

Adjuvant Phase 3 clinical trials in BRAF V600-mutant high-risk resected melanoma patients.

Phase 3 Clinical Trial	% of BRAF V600-Mutant Patients	Stage (AJCC VII Edition)	Experimental Arm	Standard Arm	Primary Endpoint in BRAF V600-Mutant Patients	Reference
BRIM-8	100%	IIC-IIIB	V	placebo	RFS: 23.1 months vs. 15.4 months (p = 0.026)	[74]
COMBI-AD	100%	III	D+T	placebo	4-year RFS: 54% vs. 38%	[73,75]
CheckMate-238	42.1%	IIIB-IV	N	I	HR for 2-year RFS: 0.79	[81]
KEYNOTE-054	43.3%	III	P	placebo	HR for 1-year RFS: 0.59	[80]

V: vemurafenib; D: dabrafenib; T: trametinib; P: pembrolizumab; N: nivolumab; I: ipilimumab; RFS: recurrence-free survival; HR: hazard ratio.